ISSN 1866-8836
Клеточная терапия и трансплантация

Synchronous skin squamous cell carcinoma and papillary thyroid carcinoma after renal transplantation: a case report

Omar Hamdy 1, Sara Raafat 2, Amr Abouzid 1, Mahmoud M. Saleh 1, Abdelhady M. Shebl 2
1 Surgical Oncology Unit, Oncology Center Mansoura University (OCMU) 2 Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
doi 10.18620/ctt-1866-8836-2018-7-4-61-65

Download PDF version

Cellular Therapy and Transplantation (CTT)
Volume 7, Number 4


Secondary malignancies following renal transplantation are not an uncommon event. In this report we considered one of the causes of posttransplant mortality. We report a renal transplant case and immune suppression treatment followed 11 years later by synchronous skin squamous cell carcinoma and papillary thyroid carcinoma that was diagnosed, presented and managed at the Oncology Center at Mansoura University.


Kidney transplantation, immunosuppressive drugs, synchronous malignancy.


Renal transplantation is considered the best treatment modality for end-stage renal disease (ESRD), off ering better survival than chronic hemodialysis. Yet, posttransplant malignancy is considered the second cause of death in renal transplant patients aft er cardiovascular diseases. Acquired immune defi ciency caused by immunosuppressive drugs is supposed of being the cause of such high incidence. Th e most common malignancy in those patients is non-melanocytic skin cancer, while thyroid cancer is not very common and does not show a higher incidence than in general population [1-4].

Case presentation

T e patient was a fift y-three year-old male, diabetic and hypertensive, married with two off springs. He had a history of renal transplantation in April, 2004 from a living donor aft er suff ering from end-stage renal disease (ESRD) secondary to hypertension. He was kept on immunosuppressant therapy, received cyclosporine (100 mg daily dose) for 11 years (2004- 2015), followed by sirolimus (1 mg daily) for 3 years (2015 till now). He has been receiving daily doses of prednisone (10 mg) and azathioprine (100 mg) from 2004 till now.
The patient had history of prior excision of right pre-auricular lesion in 2015, with histologically proven keratoacanthoma, followed aft er 6 months by wide local excision of a recurrent tumor at the same site with postoperative pathology revealing grade I squamous cell carcinoma (SCC, a primary malignancy), with free all safety margins from tumor tissue.
He was presented to our center in February 2017 complaining from right pre-auricular ulcer. Physical examination revealed good general condition with right pre-auricular ulcer, with raised everted edges, necrotic base and purulent discharge. Sonography of the neck region revealed enlarged distorted intraparotid lymph nodes, as well as an incidentally discovered left solitary thyroid nodule 1.5x1.1 cm in size, the nodule was solid, iso-echoic with calcifi cation foci, and with poorly defi ned outline, thus being classifi ed as TIRADS 5 nodule. Computed tomography (CT) examination revealed a soft tissue swelling invading the skin and involving superficial lobe of the right parotid gland measuring 3x2x1 cm. CT showed also two suspicious left cervical lymph nodes (LNs), the largest was 10x9x8 mm.
The patient underwent wide local excision of the tumor en bloc with superficial lobe of the right parotid gland, ipsilateral modifi ed radical block neck dissection, as well as left hemithyroidectomy from which frozen sections were examined, showing no evidence for malignancy. Paraffin sections prepared from the surgical specimens revealed malignant tumor proliferation formed of malignant squamoid epithelial cell foci with frequent central keratin pearls separated by desmoplastic infl ammatory stroma. Th e cells showed moderate pleomorphism, abundant eosinophilic cytoplasm, vesicular nuclei and prominent nucleoli. Th e tumor was seen to infi ltrate adjacent parotid gland, and one of three intraparotid lymph nodes, with all twenty-seven lateral LNs being unaff ected, leading to the diagnosis of pre-auricular grade I SCC infi ltrating parotid gland, with tumor-negative lateral lymph nodes. (Fig. 1). Histological sections prepared from left thyroid lobe revealed multiple nodules showing malignant tumoral proliferation consisting of papillary structures lined by cuboidal epithelial cells showing nuclear overlapping, washing out and grooving with coff ee bean appearance, thus leading to the fi nal diagnosis of papillary thyroid carcinoma (Second malignancy, Fig. 2). Two weeks later, the patient underwent completion thyroidectomy and contralateral selective block neck dissection (levels II-V) which revealed a hyperplastic thyroid nodule and a single positive lateral lymph node infiltrated by papillary thyroid carcinoma.
61-65 Figure 1. Microscopic picture of the preauricular.png
He was referred to Clinical Oncology Department for further management. In view of renal transplantation history, only one positive LN and that the patient was obsessive about nephrotoxic drugs, radioactive iodine was omitted, and the decision was to receive suppressive dose of L-thyroxine and radiotherapy on the SCC tumor bed.
Eight months later, the patient was presented with right thumb lesion. Histopatholigical examination of the biopsy showed pseudoepitheliomatous hyperplasia. Yet, wide local excision of the lesion with microscopic examination of the specimen described malignant tumoral proliferation formed of sheets and nests of malignant squamous epithelium showing moderate atypia and pleomorphism with focal central keratin pearls and dyskeratosis, thus leading to the diagnosis of grade II squamous cell carcinoma with free all safety margins from tumor tissue (Third malignancy, Fig. 3). Nine months later, he suff ered from local recurrence in his right thumb for which he underwent thumb amputation with free surgical margin.


Renal transplantation is considered the best treatment modality for patients with end-stage renal disease (ESRD) who are candidates for transplantation, with routine use of immunosuppressive therapy to prevent graft rejection. Th is makes transplantation not only a life-saving procedure, but also a life-changing one. Th e use of immunosuppressants led to increasing the risk for developing malignancy by about three- to four-fold compared to general population, with a reported incidence of 4-18%. Th e transplanted patients are considered having higher risk for both incidence and mortality from cancer, being the second leading cause of death aft er cardiovascular diseases in this cohort. Th is is usually explained by lacking immunity surveillance allowing potentially neoplastic cells to proliferate due to opportunistic oncogenic viral infections or somatic mutations, DNA damage, increased age of transplanted population, more biologically aggressive tumors, as well as using less aggressive cancer treatment modalities, concerns for suppressed immunity and higher risk of graft rejection. Eventually, some of the immunosuppressive drugs are reported to have pro-carcinogenic properties. The most common malignancies among renal transplant patients are a non-melanocytic skin cancer followed by Kaposi sarcoma. Most of them are de novo malignancies rather than those recurrent of pre-transplant malignancy, or donor-derived tumors. The incidence of cancer is increased by the duration of immunosuppressive therapy and use of steroids [5-14]. Despite the developing malignancy does not aff ect graft survival, the reduction of malignancy risk among transplant patients is very important since they experience worse outcomes with increased cancer-related mortality. Th is may be achieved by using immunosuppressive drugs with antitumor eff ects or adopting low-level immunosuppression as well as regular cancer screening of the transplanted patients [1, 9, 15]. Specifi c cancer prevention, screening and treatment programs for people with solid organ transplantation are highly recommended [4, 13].
61-65 Figure 2. Microscopic picture of malignant thyroid lob.png
61-65 Figure 3. Microscopic picture of the thumb.png
Once diagnosis of posttransplant malignancy is established, the adequate oncological management of the disease, as well as modulation of immunosuppressants should be performed, including dose reduction, withdrawal, or drug substitution, e.g., based on mammalian target of rapamycin (mTOR) inhibition. Their application is shown to be associated even with regression in non-metastatic malignancies [16, 17].
Non-melanocytic skin cancer (NMSC) is the most common malignancy in solid organ transplant patients and, especially, in renal transplant patients, with a 65-250-fold increased incidence risk. Squamous cell carcinoma is the most common NMSC type, followed by basal cell carcinoma with an incidence ratio 4:1, thus being diff erent from general population where basal cell carcinoma is more common. Besides being more aggressive, it tends to be presented in multiple sites after the initial lesion. Th e risk for developing SCC is higher in light-colored skin people and those with long-term immunosuppression with tendency for multiplicity in the sun-exposed areas and higher risk for recurrence [11]. Thyroid cancer aft er renal transplantation shows non-significant higher incidence which may be explained by the use of immunosuppressive drugs, as well as routine diagnostics by performance of neck ultrasonography, due to associated hyperparathyroidism in ESRD patients. However, its incidence is increased in ESRD patients who did not undergo transplantation as well. Th yroid cancer in renal transplant patients shows the same prognosis and rate of recurrence as for general population, despite showing diff erent gender distribution. These patients are advised to be treated with the same modalities as other thyroid cancer patients [2, 10].


Incidence of posttransplant malignancy secondary to immunosuppression is a common event, being the second leading cause of death for such patients. Non-melanocytic skin cancer is the most common malignancy aft er renal transplantation. Malignancy risk reduction among transplant patients is a must even if malignancy is not associated with worse graft outcome. Specifi c cancer prevention, screening and treatment programs for those people are highly recommended.

Conflict of interest

None declared.


1. Choi SJ, Choi D, Kwon OJ. Incidence of post-transplant malignancy aft er renal transplantation: single center analysis. J Korean Soc Transpl [Internet]. Th e Korean Society for Transplantation; 2014;28(4):204-210.
2. Kluijfh out WP, Drake FT, Pasternak JD, Beninato T, Mitmaker EJ, Gosnell JE, et al. De novo thyroid cancer following solid organ transplantation – A 25-year experience at a high-volume institution with a review of the literature. J Surg Oncol. 2017 Feb 1;115(2):105-108.
3. Wahab KA, Attia E, Arafa M, Sorogy M El, Wahab MA. Micro-invasive papillary thyroid lesion in a post living donor liver transplant patient: A case report. Int J Case Reports Images. 2016;7(5):323-326.
4. Zhang J, Ma L, Xie Z, Guo Y, Sun W, Zhang L, et al. Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review. Med Oncol. 2014;31(7):32.
5. Engberg H, Wehberg S, Bistrup C, Heaf J, Sørensen SS, Th iesson HC, et al. Cancer risk and mortality aft er kidney transplantation: a population-based study on diff erences between Danish centres using standard immunosuppression with and without glucocorticoids. Nephrol Dial Transplant. 2016;31(12):2149-2156.
6. Asch WS, Perazella MA. Cancer and mortality in solid-organ transplantation: preventable or inevitable? Am J Kidney Dis. Elsevier; 2018;68(6):839-842.
7. Wong G, Au E, Badve S V, Lim WH. Breast Cancer and Transplantation. Am J Transplant. 2017;17(9):2243-2253.
8. Tanaka T, Voigt MD. Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation. J Cancer Res Clin Oncol. 2018;144(3):607-615.
9. Pendón-Ruiz de Mier V, Navarro Cabello MD, Martínez Vaquera S, Lopez-Andreu M, Aguera Morales ML, Rodriguez- Benot A, et al. Incidence and long-term prognosis of cancer aft er kidney transplantation. Transplant Proc. Elsevier; 2018;47(9):2618-2621.
10. Lee J, Jeong JJ, Lee YS, Nam KH, Chang HS, Chung WY, et al. Incidence and Clinical behavior of papillary thyroid carcinoma in renal allograft recipients: A single center experience. Transplant Proc. Elsevier; 2008;40(10):3751-3754.
11. Amre R, Michel RP. Transplantation and Malignancy BT – Pathology of Transplantation: A Practical Diagnostic Approach. In: Michel RP, Berry GJ, editors. Cham: Springer International Publishing; 2016. p. 451-476.
12. Gao PJ, Gao J, Li Z, Hu ZP, Zhu JY. De novo malignancy aft er liver transplantation: a single-center experience of 14 cases. Ann Surg Treat Res. 2015;88(4):222–228.
13. Sa A, Ka F, Daly C, et. al. Cancer mortality among recipients of solid-organ transplantation in ontario, canada. JAMA Oncol. 2016;2(4):463-469.
14. Miyazaki T, Sato S, Kondo T, Kusaka M, Gotoh M, Saiki Y, et al. National survey of de novo malignancy aft er solid organ transplantation in Japan. Surg Today. 2018; Available from: 15. Acuna SA, Huang JW, Dossa F, Shah PS, Kim SJ, Baxter NN. Cancer recurrence aft er solid organ transplantation: A systematic review and meta-analysis. Transplant Rev. 2017;31(4):240-248.
16. Rama I, Grinyó JM. Malignancy aft er renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010;6:511.
17. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, et al. Conversion to rapamycin immunosuppression for malignancy aft er kidney transplantation. Transplant Proc. 2010;42(4):1314-1316.

Back to the list